The FDA Just Gave a Rejected Cell Therapy a Second Chance
The FDA rejected Capricor's cell therapy for Duchenne muscular dystrophy last summer, citing insufficient evidence. Now the agency has reversed course, lifting its rejection and resuming review with new Phase 3 data in hand. The August 2026 decision could bring the first treatment targeting DMD's deadliest feature: heart failure.
Last July, the FDA looked at Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy and said no. Not enough evidence, the agency argued. Manufacturing questions lingered. The rejection stung, especially for families watching their boys lose the ability to lift a fork or hug a parent.
Eight months later, the FDA changed its mind. On March 10, the agency lifted its prior rejection letter, resumed its review of the drug called deramiocel, and set a new decision deadline of August 22, 2026. No new issues flagged. No extra hoops to jump through. Just: we're back at the table.
For a rare disease community that's been burned by false hope before, this is a genuinely significant moment.
What Duchenne Does to a Kid
Duchenne muscular dystrophy (DMD) is one of the cruelest diagnoses in medicine. It's a genetic disorder, almost exclusively affecting boys, caused by the absence of a protein called dystrophin. Think of dystrophin as the shock absorber in your muscles. Without it, every movement causes microscopic damage that the body can't repair.
Kids with DMD typically lose the ability to walk by their early teens. Their hearts weaken. Their lungs struggle. Most don't survive past their 30s. It affects roughly 1 in every 3,500 to 5,000 male births, making it rare enough to be overlooked but common enough that thousands of families live with it every day.
There are approved treatments, including exon-skipping drugs and a gene therapy called Elevidys. But none of them cure the disease. None of them work for every patient. And critically, none of them directly address the heart damage that ultimately kills most Duchenne patients. That's the gap deramiocel is trying to fill.
A Therapy That Works Like a Repair Crew
Deramiocel (also known as CAP-1002) isn't a gene therapy or a traditional drug. It's a cell therapy made from cardiosphere-derived cells, which are special cells harvested from donor heart tissue. Patients receive them intravenously, like a standard infusion, every three months.
More from this issue
View full issue →
Clinical & Regulatory6 min read
Big Pharma Is Quietly Walking Away From the One Drug We'll All Need
The world's biggest drugmakers cut their antibiotic pipelines by 35% in five years, even as superbugs grow deadlier. A new report reveals a dangerous retreat from the drugs modern medicine can't function without.
Science & Discovery
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
